Immunotherapy and Lung Cancer: Exploring the Latest Research

The year 2015 marked a milestone in the treatment of lung cancer, with two new immunotherapy drugs approved for patients with advanced disease, bringing a new approach to this hard-to-treat cancer. Several other immunotherapy agents are also moving forward in clinical trials.

research, lung cancerIn the past few years, scientists have found ways to disable the molecular checkpoints, or molecular “brakes” such as PD-1 and PD-L1, that enable cancer cells to disguise themselves and fend off attack by immune system forces. New drugs of this type – checkpoint inhibitors – block the interaction between PD-1 and PD-L1, freeing the immune system’s T cells to recognize and attack cancer cells.

The checkpoint blockers first prompted excitement when tried in patients with advanced melanoma , but would they work in lung cancer? In the past, it seemed that the immune system wasn’t very effective at recognizing and attacking lung cancers. But the new drug approvals signal that immunotherapy may have an important role in treating lung cancer, the leading cancer killer.

One of the two newly approved drugs, Opdivo (nivolumab), demonstrated a survival advantage over chemotherapy in patients with squamous or non-squamous non-small cell lung cancer (NSCLC) who were no longer responding to treatment.

A second drug, Keytruda (pembrolizumab), was approved in October for patients with squamous and non-squamous NSCLC whose tumors contain high levels of PD-L1. Those tumors were found to respond better to Keytruda than those will low levels of PD-L1.

Some patients had long-lasting responses to the powerful immunotherapy agents, and researchers are eager to find out if the drugs could hit even harder if given as first-line treatment instead of chemotherapy. Those trials are now underway.

Another checkpoint blocker, atezolizumab, blocks the interaction between PD-1 and PD-L1, and has been designated a “breakthrough therapy” by the Food and Drug Administration (FDA) for NSCLC that tests positive for PD-L1. It is currently in phase 3 trials. Two other drugs that block the PD-1 checkpoint, durvalumab and avelumab, are also being tested in phase 3 clinical trials to see if they offer advantages over the early checkpoint blockers.

Despite the intriguing promise of immunotherapy in lung and other cancers, it’s important – and sobering – to know that so far they work in only about 20 percent of patients. Scientists hope to find ways of improving these response rates. They’re also looking for biomarkers that can identify which patients are most likely to benefit from particular immunotherapies. One such biomarker is the presence of PD-L1 in lung tumors, which increases the odds the checkpoint blockers will work. There’s a long way to go, though, in identifying likely responders to immunotherapy drugs.

“The development of these agents that use a new method of attacking lung cancer cells is a welcome addition to our choice of therapies,” says Bruce Johnson, MD, a thoracic oncologist and chief clinical research officer at Dana-Farber Cancer Institute. “We look forward to the ongoing research which will likely reveal new ways of administering the drugs that will enhance their effectiveness in our patients.”

Learn about other new developments in lung cancer treatment, such as precision medicine, in the video below:

Comments Sort By Newest

One thought on “Immunotherapy and Lung Cancer: Exploring the Latest Research

  1. My husband was on Opdivo for 6 months for lung cancer,after chemo and radiation failed. all Opdivo did was run his system way down and the cancer kept growing.We are looking for any new treatments that might help.

  2. My husband was on Opdivo for 6 months for lung cancer,after chemo and radiation failed. all Opdivo did was run his system way down and the cancer kept growing.We are looking for any new treatments that might help.

Comments are closed.

Make An Appointment

For adults: 877-442-9599

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Facing only months to live, Doron Broman came to Dana-Farber hoping for a miracle. Today, Broman is cancer-free:… https://t.co/Mj6jpuPh46
Dana-Farber @danafarber
Expanding access to #bloodcancer clinical trials is the mission of the Blood Cancer Research Partnership:… https://t.co/aGmG83xMSd
Dana-Farber @danafarber
It's Healthcare Decisions Month. Have you thought about your future health care preferences? Here's why you should:… https://t.co/XeRe0BDppf

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.